News
Data are Consistent with Phase 2 Double-Blind Trial and Support Advancement of ATH434 in MSA – MELBOURNE, Australia and SAN FRANCISCO, (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ...
Anavex Life Sciences Corp. (NASDAQ:AVXL) announced the latest findings on Thursday for blarcamesine, an oral small molecule ...
Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented ...
Stockhead on MSN4d
Alterity reports positive results from open-label phase II trial of neurological disease drug
Alterity Therapeutics reports positive topline results from open-label phase II clinical trial of lead drug ATH434 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback